Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors

Haematologica

Volumn 99, Issue 7, 2014, Pages 1191-1196

  Kim, Sung Hyun ^a   Menon, Hari ^b   Jootar, Saengsuree ^c   Saikia, Tapan ^d   Kwak, Jae Yong ^e   Sohn, Sang Kyun ^f   Park, Joon Seong ^g   Jeong, Seong Hyun ^g   Kim, Hyeoung Joon ^h   Kim, Yeo Kyeoung ^h   Oh, Suk Joong ⁱ   Kim, Hawk ^j   Zang, Dae Young ^k   Chung, Joo Seop ^l   Shin, Ho Jin ^l   Do, Young Rok ^m   Kim, Jeong A ⁿ   Kim, Dae Young ^o   Choi, Chul Won ^p   Park, Sahee ⁿ   Park, Hye Lin ^q   Lee, Gong Yeal ^q   Cho, Dae Jin ^q   Shin, Jae Soo ^q   Kim, Dong Wook ^n,r   more..

^a Dong A University   (South Korea)

^b TATA MEMORIAL HOSPITAL   (India)

^c MAHIDOL UNIVERSITY   (Thailand)

^d Prince Aly Khan Hospital   (India)

^e Chonbuk National University Medical School   (South Korea)

^f Kyungpook National University Hospital   (South Korea)

^g Ajou University Medical CentSuwon   (South Korea)

^h Chonnam National University Research Institute of Medical Sciences   (South Korea)

ⁱ Sungkyunkwan University School of Medicine   (South Korea)

^j University of Ulsan College of Medicine   (South Korea)

^k Hallym University   (South Korea)

^l Pusan National University School of Medicine   (South Korea)

^m Dongsan Medical Center   (South Korea)

ⁿ The Catholic University of Korea   (South Korea)

^o University of Ulsan College of Medicine   (South Korea)

^p Korea University College of Medicine   (South Korea)

^q Central Research Institute   (South Korea)

^r The Catholic University of Korea   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BCR ABL PROTEIN; CREATININE; DASATINIB; IMATINIB; LIVER ENZYME; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; RADOTINIB; SUPECT; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DEATH; DECREASED APPETITE; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEPATITIS; HUMAN; HYPERBILIRUBINEMIA; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERMAGNESEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; MYALGIA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHILADELPHIA 1 CHROMOSOME; POLYMERASE CHAIN REACTION; PROGRESSION FREE SURVIVAL; PRURITUS; QT PROLONGATION; RASH; SEPSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DRUG RESISTANCE; FEMALE; GENETICS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; MORTALITY; MUTATION; REMISSION; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZAMIDES; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; MUTATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REMISSION INDUCTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84903650301     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.096776     Document Type: Article

References (31)

1. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341(3):164-72.
2. Deininger MWN, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96(10):3343-56.
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™. Chronic Myelogenous Leukemia. Version 3.2013. Updated 2013. Available from: http://www.nccn.org/professionals/ physician_gls/PDF/cml.pdf
4. Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009; 23(6):1054-61.
5. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293(5531):876-80.
6. Hochhaus A, Kreil S, Corbin AS, La RP, Muller MC, Lahaye T, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002; 16(11):2190-6.
7. Kim SH, Kim D, Kim DW, Goh HG, Jang SE, Lee J, et al. Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent. Hematol Oncol. 2009;27(4):190-7.
8. Shah NP. Loss of response to imatinib: mechanisms and management. Hematology Am Soc Hematol Educ Program. 2005;183-7.
9. Kim D, Goh HG, Kim SH, Choi SY, Park SH, Jang EJ, et al. Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea: feasibility assessment of current ELN recommendation. Int J Hematol. 2012;96(1):47-57.
10. Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst. 2011;103(7):553-61.
11. Mauro MJ. Defining and managing imatinib resistance. Hematology Am Soc Hematol Educ Program. 2006;219-25.
12. Jabbour E, Cortes J, O'Brien S, Giles F, Kantarjian H. New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance. Semin Hematol. 2007;44(1 Suppl 1):S25-S31.
13. Cortes J, Goldman JM, Hughes T. Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure. J Natl Compr Canc Netw. 2012;10 Suppl 3:S1-S13.
14. Santos FP, Kantarjian H, Quintas-Cardama A, Cortes J. Evolution of therapies for chronic myelogenous leukemia. Cancer J. 2011;17(6):465-76.
15. Jootar S. CML treatment in Asia-Pacific region. Hematology. 2012;17(Suppl 1):S72-S74.
16. Au WY, Caguioa PB, Chuah C, Hsu SC, Jootar S, Kim DW, et al. Chronic myeloid leukemia in Asia. Int J Hematol. 2009; 89(1):14-23.
17. Kim DW, Banavali SD, Bunworasate U, Goh YT, Ganly P, Huang H, et al. Chronic myeloid leukemia in the Asia-Pacific region: current practice, challenges and opportunities in the targeted therapy era. Leuk Res. 2010;34(11):1459-71.
18. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013;121(22):4439-42.
19. Kim SH, Hari M, Jootar S, Saikia T, Kwak JY, Sohn SK, et al. Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL tyrosine kinase inhibitors: radotinib phase 2 clinical trial. ASH Annual Meeting Abstracts. Blood. 2012;120.
20. Lee J, Han BC, Goh HG, Kim SH, Kim WS, Yoo JS, et al. IY5511, a novel Bcr-Abl tyrosine kinase inhibitor, is highly active compound in inhibition of CrkL phosphorylation and in xenograft animal chronic myeloid leukemia model. ISH-APD. APBMT Meeting Abstract. 2007;02-061.
21. Lee J, Kim HJ, Sohn S-K, Kwak J-Y, Park JS, Zang DY, et al. Safety and efficacy of radotinib, a tyrosine kinase inhibitor. Korean J Hematol. 2011;46(suppl 2):152.
22. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009; 27(35):6041-51.
23. Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronicphase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007; 109(6):2303-9.
24. Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110(10):3540-6.
25. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013. [Epub ahead of print]
26. Quintas-Cardama A, Han X, Kantarjian H, Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood. 2009; 114(2):261-3.
27. Quintas-Cardama A, Kantarjian H, O'Brien S, Borthakur G, Bruzzi J, Munden R, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007;25(25):3908-14.
28. Abbott BL. Dasatinib: from treatment of imatinib-resistant or-intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia. Clin Ther. 2012;34(2):272-81.
29. Kim D, Goh HG, Kim SH, Cho BS, Kim DW. Long-term pattern of pleural effusion from chronic myeloid leukemia patients in second-line dasatinib therapy. Int J Hematol. 2011;94(4):361-71.
30. Giles FJ, Mauro MJ, Hong F, Ortmann CE, McNeill C, Woodman RC, et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia. 2013;27(6):1310-5.
31. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354(24):2542-51.